{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:59:58Z","timestamp":1787853598835,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejca.2018.11.031","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T20:19:00Z","timestamp":1546633140000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-861X","authenticated-orcid":false,"given":"Marie","family":"Auvray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirkko","family":"Kellokumpu-Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8075-0666","authenticated-orcid":false,"given":"Guillermo","family":"De Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-7461","authenticated-orcid":false,"given":"Guillaume","family":"Mouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann-Alexandre","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2018.11.031_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.11.031_bib2","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","author":"Motzer","year":"2013","journal-title":"Research-article"},{"key":"10.1016\/j.ejca.2018.11.031_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ejca.2018.11.031_bib4","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.031_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol. 1 mars"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2018.11.031_bib6","doi-asserted-by":"crossref","first-page":"v58-68","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2018.11.031_bib7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J Natl Compr Canc Netw. 1 juin"},{"issue":"4","key":"10.1016\/j.ejca.2018.11.031_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med. 26 janv"},{"issue":"8","key":"10.1016\/j.ejca.2018.11.031_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol. ao\u00fbt"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.031_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol. mars"},{"issue":"9146","key":"10.1016\/j.ejca.2018.11.031_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-\u03b1 and survival in metastatic renal carcinoma: early results of a randomised controlled trial","volume":"353","year":"1999","journal-title":"The Lancet. 2 janv"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2018.11.031_bib12","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am. f\u00e9vr"},{"issue":"13","key":"10.1016\/j.ejca.2018.11.031_bib13","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.031_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med. 11 juill"},{"issue":"34","key":"10.1016\/j.ejca.2018.11.031_bib15","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.031_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated european association of urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2018","journal-title":"Eur Urol. mars"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.031_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","article-title":"On the exact distribution of maximally selected rank statistics","volume":"43","author":"Hothorn","year":"2003","journal-title":"Comput Stat Data Anal. juin"},{"issue":"6","key":"10.1016\/j.ejca.2018.11.031_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol. 20 f\u00e9vr"},{"issue":"17","key":"10.1016\/j.ejca.2018.11.031_bib19","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.ejca.2015.08.017","article-title":"Efficacy of targeted therapies after PD-1\/PD-L1 blockade in metastatic renal cell carcinoma","volume":"51","author":"Albiges","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"7","key":"10.1016\/j.ejca.2018.11.031_bib20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdw160","article-title":"Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)\u2013tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma","volume":"27","author":"Nadal","year":"2016","journal-title":"Ann Oncol. 1 juill"},{"issue":"6","key":"10.1016\/j.ejca.2018.11.031_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.ejca.2018.11.031_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med. juin"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.031_bib23","first-page":"581","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell. 19 avr"},{"issue":"4","key":"10.1016\/j.ejca.2018.11.031_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","article-title":"Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma","volume":"72","author":"Pal","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ejca.2018.11.031_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Tartour","year":"2011","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"10.1016\/j.ejca.2018.11.031_bib26","first-page":"205","article-title":"Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis","volume":"20","author":"Kuusk","year":"2017","journal-title":"mai"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2018.11.031_bib27","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol. 20 mai"},{"issue":"3","key":"10.1016\/j.ejca.2018.11.031_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.11.031_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ejca.2018.11.031_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.11.031_bib31","first-page":"1","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"24","author":"Barata","year":"2018","journal-title":"Br J Canc"},{"issue":"6_suppl","key":"10.1016\/j.ejca.2018.11.031_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.682","article-title":"Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI)","volume":"36","author":"Shah","year":"2018","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2019.04.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:06:53Z","timestamp":1549307213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"alternative-id":["S0959804918315399"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.031","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2019.04.012","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}